ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price soar 5.26% in Tuesday's intraday trading session following the release of its full-year 2024 financial results.
While the biotechnology company reported a net loss of $413.6 million for the year, this figure represented a 29% narrowing of losses compared to the previous year. Additionally, ImmunityBio's earnings per share (EPS) surpassed analyst expectations, despite revenue falling short of estimates.
Looking ahead, the company forecasts an impressive 55% annual revenue growth on average over the next three years, outpacing the 20% growth forecast for the broader American biotechs industry. However, investors are advised to consider the four warning signs identified by analysts, including three significant ones, which may impact the company's future performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。